Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells

Oncogene

Volumn 26, Issue 13, 2007, Pages 1954-1958

  Liu, J ^a   Suresh Kumar, K G ^a   Yu, D ^a   Molton, S A ^b   McMahon, M ^b   Herlyn, M ^c   Thomas Tikhonenko, A ^a   Fuchs, S Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Trcp; BRAF; I B kinase; Melanoma; NF B

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 HYDROXYTAMOXIFEN; B RAF KINASE; ENZYME BETA TRCP; I KAPPA B KINASE; SHORT HAIRPIN RNA; SORAFENIB; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROLYSIS; MELANOMA; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE;

EID: 33947527353     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209994     Document Type: Article

References (22)

1. Amiri KI, Richmond A. (2005). Role of nuclear factor-kappa B in melanoma. Cancer Metast Rev 24: 301-313.
2. Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR et al. (2000). Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci USA 97: 4615-4620.
3. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C et al. (2002). The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17: 525-535.
4. Fuchs SY, Spiegelman VS, Kumar KG. (2004). The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23: 2028-2036.
5. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202.
6. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J et al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999-1006.
7. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J et al. (2004). Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/ extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 64: 3428-3435.
8. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T et al (2003). Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63: 8132-8137.
9. Karin M, Ben-Neriah Y. (2000). Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.
10. Norris JL, Baldwin Jr AS. (1999). Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J Biol Chem 274: 13841-13846.
11. Panka DJ, Wang W, Atkins MB, Mier JW. (2006). The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66: 1611-1619.
12. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759.
13. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421.
14. Smalley KS. (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104: 527-532.
15. Smalley KS, Herlyn M. (2005). Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann NY Acad Sci 1059: 16-25.
16. Soldatenkov VA, Dritschilo A, Ronai Z, Fuchs SY. (1999). Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res 59: 5085-5088.
17. Spiegelman VS, Tang W, Chan AM, Igarashi M, Aaronson SA, Sassoon DA et al. (2002a). Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem 277: 36624-36630.
18. Spiegelman VS, Tang W, Katoh M, Slaga TJ, Fuchs SY. (2002b). Inhibition of HOS expression and activities by Wnt pathway. Oncogene 21: 856-860.
19. Ueda Y, Richmond A. (2006). NF-kappaB activation in melanoma. Pigment Cell Res 19: 112-124.
20. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. (2006). BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12: 950-960.
21. Yang J, Richmond A. (2001). Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61: 4901-4909.
22. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. (1997). The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91: 243-252.